Psychopharmacology of Schizophrenia in Children and Adolescents

Carlisle, L. Lee; McClellan, Jon

doi:10.1016/j.pcl.2010.11.006

Cited by 13 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are also references with lower figures with a prevalence of 1 per 500-10,000 in mid-adolescence (10). The prevalence of COS is even lower, generally quoted as 1 in 10,000 (3,(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

“…Schizophrenia can occur at any age from childhood to late adulthood. Typically the onset of symptoms is in late adolescence or early adulthood, although cognitive impairments and behavioral changes can be recognized at an earlier age (3). While people with schizophrenia have two-to threefold higher mortality, the course of the disease along with the arising comorbidities with age require special attention in elderly patients (1).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data

et al. 2020

View full text Add to dashboard Cite

Schizophrenia is a lifelong mental disorder, affecting young adolescents to elderly patients. Antipsychotic treatment is indicated for all patients with schizophrenia, including the very young and old as well. Developmental issues in the young and decline in organ functioning in the elderly could influence reactions to the drug, and require different dosing regimens. The aim of the present article was to examine the safety profile and dosing requirements in adolescent (13 to less than 18) and elderly (65 and above) patients treated with cariprazine. Data from two clinical studies (one pharmacokinetic pediatric study and one phase III clinical trial) on 49 adolescent patients and 17 elderly patients (65 years of age or above) treated with cariprazine was examined. Safety measures included assessment of adverse events (AEs), clinical laboratory values, physical examinations, extrapyramidal symptom (EPS)-, depression-, and suicidality rating scales. Safety parameters were summarized using descriptive statistics. Results indicate that cariprazine was generally safe and well tolerated. Adverse events in the marginal age populations were comparable to the adult population, except for less insomnia in the young and no reports of akathisia in the elderly. Laboratory parameters, vital sign values and EEG parameters were comparable to previously published data in the adult population. In conclusion, cariprazine in the approved adult dose-range of 1.5-6 mg might be a safe treatment option also in adolescent and elderly patients with schizophrenia. Further studies are need to verify these preliminary findings.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Lifetime prevalence rates from this study are 8.7% for ADHD, 13.6% for other behavioral disorders, 31.9% for anxiety disorders, 11.4% for SUD, and 14.3% for mood disorders [4]. Schizophrenia rates were not reported in these studies, probably because it is rare in children and adolescents, having an estimated prevalence rate of about 0.01% [6].…”

Section: Introductionmentioning

confidence: 56%

White matter abnormalities in psychiatric disorders

Lindquist

2015

J Pediatr Neuroradiol

View full text Add to dashboard Cite

This article reviews the reports of white matter abnormalities in several psychiatric disorders. Volumetric differences found by voxel-based morphometry or region-of-interest analysis of structural magnetic resonance imaging studies are described. Abnormalities in the diffusion metrics, primarily fractional anisotropy and mean diffusivity, from diffusion tensor imaging studies are also summarized. The consensus is that there are widespread abnormalities in white matter in psychiatric disorders, but no particular region has been identified as specific to any one disease. Instead, these diseases seem to impact commonly the corpus callosum and superior longitudinal fasciculus, as well as several other connecting tracts. Neuroimaging has provided significant insights into the aberrant white matter in these diseases, but more work is required to understand the timing, progression, and underlying pathophysiology of these abnormalities.

show abstract

“…Carlisle and McClellan (2011) note that there have been 11 published randomized controlled trials of antipsychotic medication use in children and adolescents. Many first‐ and second‐generation agents have positive effects on symptoms.…”

mentioning

confidence: 99%

“…This makes focused, successful interventions aimed at preventing weight gain early in treatment or implementing weight loss strategies after weight gain even more challenging. Carlisle and McClellan (2011) note that there have been 11 published randomized controlled trials of antipsychotic medication use in children and adolescents. Many first-and second-generation agents have positive effects on symptoms.…”

mentioning

confidence: 99%

Managing the Metabolic Side Effects of Atypical Antipsychotics

Pearson

2012

Child Adoles Psych Nursing

View full text Add to dashboard Cite

Psychopharmacology of Schizophrenia in Children and Adolescents

Cited by 13 publications

References 33 publications

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data

White matter abnormalities in psychiatric disorders

Managing the Metabolic Side Effects of Atypical Antipsychotics

Contact Info

Product

Resources

About